This listing of claims will replace all prior versions, and listings, of claims in the application.

I. Listing of Claims:

1. **(Canceled)**
2. **(Canceled)**
3. **(Canceled)**
4. **(Canceled)**
5. **(Canceled)**
6. **(Canceled)**
7. **(Canceled)**
8. **(Canceled)**
9. **(Canceled)**
10. **(Canceled)**
11. **(Canceled)**
12. **(Canceled)**
13. **(Canceled)**
14. **(Canceled)**
15. **(Canceled)**

16. **(Canceled)**

17. **(Canceled)**

18. **(Canceled)**

19. **(Canceled)**

20. **(Canceled)**

21. **(Canceled)**

22. **(Canceled)**

23. **(Canceled)**

24. **(Canceled)**

25. **(Canceled)**

26. **(Canceled)**

27. **(Canceled)**

28. **(Canceled)**

29. **(Canceled)**

30. **(Canceled)**

31. **(Canceled)**

32. **(Canceled)**

33. **(Canceled)**

34. **(Canceled)**

35. **(Canceled)**

36. **(Canceled)**

37. **(Currently amended)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate ~~a member selected from the group consisting of amphetamine, dextroamphetamine, methamphetamine, phenylisopropylamine, pemoline,~~ and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 5.5 hours following said administration~~, in a sustained and increasing dose for treating Attention-Deficit Disorder in the patient~~.

38. **(Canceled)**

39. **(Canceled)**

40. **(Canceled)**

41. **(Canceled)**

42. **(Canceled)**

43. **(Canceled)**

44. **(Canceled)**

45. **(Canceled)**

Sub C'

46. (**new**) The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 4 to about 5.5 hours.

47. (**new**) The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 8 hours.

48. (**new**) The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 9.5 hours.

B' Cancel

49. (**new**) A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 8 hours following said administration.

50. (**new**) A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 9.5 hours following said administration.